Maintenance Therapy in NSCLC: Bevacizumab, Pemetrexed, or Both? (ECOG-ACRIN 5508)

On July 30, 2019, Suresh S. Ramalingam and colleagues published the results of the ECOG-ACRIN 5508 Phase 3 clinical trial in the Journal of Clinical Oncology. This study compared the efficacy and safety of single-agent Bevacizumab (Avastin), single-agent Pemetrexed (Alimta), and their combination as maintenance therapy for patients with advanced non-squamous non-small cell lung cancer (NSCLC).

Study Design: ECOG-ACRIN 5508 Trial

The trial randomized patients with untreated non-squamous NSCLC who had not progressed after induction therapy with Carboplatin, Paclitaxel, and Bevacizumab into three maintenance groups:

1. Bevacizumab Monotherapy
2. Pemetrexed Monotherapy
3. Bevacizumab + Pemetrexed Combination

The primary endpoint was overall survival (OS).

Key Survival Results (Median Follow-up 50.6 Months)

Overall Survival (OS)

• Bevacizumab Group: 15.9 months
• Pemetrexed Group: 14.4 months
• Combination Group: 16.4 months
• There were no statistically significant differences in OS between the three arms.

Progression-Free Survival (PFS)

• Bevacizumab Group: 4.2 months
• Pemetrexed Group: 5.1 months
• Combination Group: 7.5 months
• The combination group showed a longer PFS, but this did not translate into a significant OS benefit.

Safety and Toxicity

The incidence of Grade 4 adverse events was highest in the combination group (51%), compared to 30% in the Bevacizumab group and 38% in the Pemetrexed group.

• Pemetrexed-related toxicities: Anemia, fatigue, and neutropenia.
• Bevacizumab-related toxicities: Hypertension and proteinuria.

Conclusion

Dr. Suresh S. Ramalingam concluded that both Bevacizumab and Pemetrexed are effective as single-agent maintenance therapies for non-squamous NSCLC. Given the increased toxicity and lack of overall survival benefit with the combination, single-agent maintenance is generally recommended.

Source: Journal of Clinical Oncology - ECOG-ACRIN 5508 Results

#LungCancer #NSCLC #Bevacizumab #Avastin #Pemetrexed #Alimta #MaintenanceTherapy

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5